Canine liver enzymes – FAQs
Blood sampling for assessment of liver status is an everyday occurrence in practice, but interpretation of the results can be more difficult than it first appears to be.
Issue number 34.2 Other Scientific
Published 31/01/2025
Also available in Français , Deutsch , Italiano and Español
Not sure about how to use C-reactive protein assays? This paper offers seven key pointers to successfully incorporating it into everyday clinical practice.
C-reactive protein (CRP) can be used routinely in first opinion practice in many situations, assuming the available assay is adequately validated.
CRP can be used not only to detect an inflammatory response, but also to aid in diagnosis of the underlying cause.
In inflammatory conditions, CRP is particularly useful for monitoring of treatment and predicting disease occurrence.
CRP values should be interpreted in the context of the entire clinical picture and available information, and alongside other acute phase proteins if possible.
C-reactive protein (CRP) is an acute phase protein (APP), a term that describes proteins whose concentration changes in response to inflammation or immune system stimulation, regardless of the cause. CRP is generated quickly, with significant increases observed just a few hours after the inflammatory stimulus (e.g., 4 hours after a surgical intervention), and peak concentrations are reached at approximately 24 hours. This reaction is part of the innate immune response, which means that it is rapid and non-specific, and it can be triggered by any process that damages the animal 1. After more than 20 years of using and providing external services for CRP measurement at our laboratory, we have found that practitioners who regularly use CRP consider it to be one of the most important biomarkers of inflammation. Included as a part of their routine analytical profiles, CRP assay is employed for periodic check-ups, diagnostics, treatment monitoring, and predicting the outcome of inflammatory disease. This seven-point review will provide updated information and practical examples on how CRP can be employed in clinical practice, and will follow the initial consensus established some years ago about the use of CRP in companion animals 1.
Any method used to assess CRP in practice must be validated to ensure the results can be trusted. Various manufacturers currently offer certified in-house (“benchtop”) canine-specific tests, and the larger clinical pathology laboratories also provide assays. Although certain human assays may not be suitable for dogs, others can be effective and provide a cost-efficient means of measuring CRP 2. However, it is always to be recommended that standardization of the assay (using purified protein or pools of acute phase serum) and control samples should be of canine origin.
Serum, EDTA or heparinized plasma can be employed for CRP measurements, and because the protein is fairly stable, samples can be refrigerated for several days or frozen for long-term preservation. It is important to know the effect of hemolysis, lipemia and bilirubinemia on the CRP values obtained, as the effects can vary depending on the method used. In our laboratory, the reference range for CRP in healthy dogs is below 12 mg/L, and whilst this value can vary between laboratories, it is usually not higher than 20 mg/L. There are no evident changes in reference ranges due to age or gender, although in pregnant bitches CRP increases at 21 days after fertilization, coinciding with embryonic implantation.
The possibility of using CRP along with other APPs will be considered later, but the different APPs will be described here. APPs that increase concentration after an inflammatory stimulus are known as POSITIVE APPs, while others that decrease after such a stimulus are called NEGATIVE APPs (Figure 1).
Positive APPs are further classified into two groups, namely major and moderate: Major APPs in dogs are CRP and serum amyloid A (SAA). While these proteins are present in low level in healthy animals, their concentration can increase by 10-100 times when stimulated. Moderate APPs are haptoglobin (Hp), ferritin and fibrinogen. Their concentrations increase 2-10-fold following stimulation. Major APPs exhibit a rapid increase in concentration followed by a steep decline, usually within hours, while moderate APPs take longer to both increase from and return to normal levels.
Albumin and paraoxonase-1 (PON-1) are examples of negative APPs. During inflammation, the albumin serum concentration decreases. This may be because albumin is the most abundant protein in serum, and its decrease can promote the synthesis of other proteins related to inflammation. PON-1 has an antioxidant function, and its decrease in inflammatory processes is possibly due to the associated oxidative stress that consumes this protein.
The main reason to use a CRP assay is to confirm or rule out an inflammatory or infectious process. Whilst the most widely used tool for detecting inflammation is the evaluation of white blood cells (WBCs), ideally CRP should be measured and interpreted at the same time. Moreover, CRP has several advantages over WBCs in detecting and evaluating the severity of inflammation, especially as it has better sensitivity. For example, higher sensitivity of CRP has been reported in cases of babesiosis (Figure 2) 3 or various surgical procedures 4, and this is particularly important where there is decreased bone marrow activity. In addition, CRP is highly stable, allowing for long-term storage of samples, which is not possible with WBCs.
Whilst elevated CRP levels are very useful in detecting inflammation in the dog, it is important to note that a CRP within the reference range is also a significant clinical finding, as it suggests the absence of an acute inflammatory or infectious process. In addition to detect or rule out inflammation, CRP can also provide additional information for the clinician, as shown in Table 1.
Table 1. What information can CRP provide beyond detecting inflammation?
Additional information | Examples |
Evaluate the severity of the inflammation or inflammatory disease. This is because increases in CRP are usually related to the magnitude of the inflammation. |
|
An increase in CRP in conditions where it is usually within the reference range may indicate the presence of complications or a severe form of the disease. |
|
José Cerón
Although CRP cannot identify the cause of inflammation, due to its non-specific nature, its magnitude of increase can help to narrow down the list of possible causes and guide the diagnostic process (Table 2; Figure 3). This can lead to various practical applications, as outlined in Table 3. In addition, it is important to note that there are situations where CRP may significantly aid in differentiating between the causes of a problem, such as:
Table 2. Clinical interpretation of the magnitude of serum CRP increase in dogs (from 11).
CRP (mg/L) | Comment |
0-12 | Normal (the reference range can vary depending on the laboratory) |
12-20 |
Slight increase of uncertain diagnostic value:
|
20-39 |
Increased levels:
|
40-100 |
Significantly increased levels:
|
> 100 |
Severe inflammation:
|
Table 3. Potential usefulness of CRP in narrowing the list of causes and guiding diagnosis.
Application and explanation | Examples |
Suspicion of sepsis or immune-mediated disorder: Increases in CRP > 100 mg/L are usually associated with either SIRS, which in the case of a positive bacterial culture could indicate sepsis, or an immune-mediated disorder. |
|
Suspicion of an infectious-inflammatory cause: Where clinical signs could be caused by either inflammatory or non-inflammatory factors, a CRP level above the reference range indicates a possible infectious-inflammatory cause. |
|
This point only refers to CRP measurement as a stand-alone test, but additional examples of how CRP can be used in combination with other APPs to identify the cause of certain conditions are discussed below.
CRP values returning to normal levels in an infectious-inflammatory disease indicates that a dog is responding to treatment and implies a good prognosis. This has been demonstrated in numerous inflammatory diseases, such as acute pancreatitis, where CRP can be a useful tool for monitoring clinical progression and response to treatment 19. CRP has been shown to better reflect the evolution of inflammation after treatment compared to WBCs in conditions such as immune-mediated polyarthritis, indicating periods of relapse and remission of the disease 20. Examples of interpretation are:
CRP’s high sensitivity and fast stimulation of response allow detection of subclinical inflammation, with changes in APPs occurring before clinical signs develop. Therefore, this protein is highly suitable for routine health checks, where an increase in APPs in an apparently healthy animal can indicate the presence of a subclinical disease or predict the development of active disease in the near future. For example, in a study on dogs infected with Babesia gibsoni, high concentrations of CRP were documented despite the absence of obvious clinical signs or parasitemia 22. Similarly, high CRP values are reported in asymptomatic dogs infected with Leishmania infantum – and it can be assumed that these animals may develop clinical signs at a later stage 23.
Divergences between major and moderate APPs can provide useful clinical information, so if possible, it is recommended to use a laboratory profile that includes at least one major and one moderate APP. The term “divergence” describes a situation where APPs of the two groups do not change as expected in the presence of an inflammatory stimulus. Some relevant examples are:
Asta Tvarijonaviciute
CRP is a valuable diagnostic tool in routine canine practice and is an excellent assay to incorporate when testing both in disease situations and in routine health screens. It is expected that the information present in this paper will assist practitioners already using CRP to maximize its benefits, and encourage those unfamiliar with CRP to consider its applications. This review will provide updated information and practical examples on how CRP can be employed in clinical practice, and will follow the initial consensus based on a seven point plan established some years ago about the use of CRP in companion animals 1.
Conflict of interest statement; Neither author has a financial or personal relationship with other people or organizations that could inappropriately influence or bias the content of the paper. |
AcknowledgementThe authors would like to dedicate this work to Dr. Marco Caldin, one of the pioneers and main contributors to the application of CRP in canine practice; his vision, knowledge and legacy is a continuous source of inspiration to us and other many researchers in this field. The authors would also like to thank Silvia Martinez-Subiela for her advice and help in the preparation of this manuscript. |
Cerón JJ. Acute phase proteins, saliva and education in laboratory science: an update and some reflections. BMC Vet. Res. [Internet]. 2019;15(1):197. Available from: https://pubmed.ncbi.nlm.nih.gov/31189466/
Muñoz Prieto A, Tvarijonaviciute A, Escribano D, et al. Use of heterologous immunoassays for quantification of serum proteins: The case of canine C-reactive protein. PLoS One 2017;12(2);e0172188. Available from: https://pubmed.ncbi.nlm.nih.gov/28222144
Matijatko V, Mrljak V, Kiš I, et al. Evidence of an acute phase response in dogs naturally infected with Babesia canis. Vet. Parasitol. 2007;144(3-4):242-250. Available from: https://pubmed.ncbi.nlm.nih.gov/17116368/
Yamamoto S, Shida T, Miyaji S, et al. Changes in serum C-reactive protein levels in dogs with various disorders and surgical traumas. Vet. Res. Commun. 1993;17(2):85-93. Available from: https://pubmed.ncbi.nlm.nih.gov/8212527/
Mylonakis ME, Cerón JJ, Leontides L, et al. Serum acute phase proteins as clinical phase indicators and outcome predictors in naturally occurring canine monocytic ehrlichiosis. J. Vet. Intern. Med. 2011;25(4):811-817. Available from: https://pubmed.ncbi.nlm.nih.gov/21564293/
Tecles F, Caldín M, Zanella A, et al. Serum acute phase protein concentrations in female dogs with mammary tumors. J. Vet. Diagn. Invest. 2009;21(2):214-219. Available from: https://pubmed.ncbi.nlm.nih.gov/19286500/
Manachai N, Umnuayyonvaree D, Punyathi P, et al. Impact of serum C-reactive protein level as a biomarker of cancer dissemination in canine lymphoid neoplasia. Vet. World 2022;15(12):2810-2815. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36718344
Martínez-Subiela S, Bernal LJ, Tvarijonaviciute A, et al. Canine demodicosis: the relationship between response to treatment of generalized disease and markers for inflammation and oxidative status. Vet. Dermatol. 2014;25(2):72-76, e23-4. Available from: https://pubmed.ncbi.nlm.nih.gov/24800264/
McCann TM, Ridyard AE, Else RW, et al. Evaluation of disease activity markers in dogs with idiopathic inflammatory bowel disease. J. Small Anim. Pract. 2007;48(11):620-625.
Segarra S, Martínez-Subiela S, Cerdà-Cuéllar M, et al. Oral chondroitin sulfate and prebiotics for the treatment of canine inflammatory bowel disease: A randomized, controlled clinical trial. BMC Vet. Res. 2016;10:12(1);49.
Cerón JJ, Martinez-Subiela S, Tecles F, et al. Acute phase proteins in diagnostics: more than expected. J. Hellenic Vet. Med. Soc. 2017;65(3):197-204. Available from: https://ejournals.epublishing.ekt.gr/index.php/jhvms/article/view/15535
Viitanen SJ, Laurila HP, Lilja-Maula LI, et al. Serum C-reactive protein as a diagnostic biomarker in dogs with bacterial respiratory diseases. J. Vet. Intern. Med. 2014;28(1):84-91. Available from: https://pubmed.ncbi.nlm.nih.gov/24351049/
Kocaturk M, Martinez S, Eralp O, et al. Prognostic value of serum acute-phase proteins in dogs with parvoviral enteritis. J. Small Anim. Pract. 2010;51(9):478-483. Available from: https://pubmed.ncbi.nlm.nih.gov/20630018/
Ohno K, Yokoyama Y, Nakashima K, . C-reactive protein concentration in canine idiopathic polyarthritis. J. Vet. Med. Sci. 2006;68(12):1275-1279. Available from: https://pubmed.ncbi.nlm.nih.gov/17213695/
Bathen-Noethen A, Carlson R, Menzel D, et al. Concentrations of acute-phase proteins in dogs with steroid responsive meningitis-arteritis. J. Vet. Intern. Med. 2008;22(5):1149-1156. Available from: https://pubmed.ncbi.nlm.nih.gov/18691368/
Fransson BA, Karlstam E, Bergstrom A, et al. C-reactive protein in the differentiation of pyometra from cystic endometrial hyperplasia/mucometra in dogs. J. Am. Anim. Hosp. Assoc. 2004;40(5):391-399. Available from: https://pubmed.ncbi.nlm.nih.gov/15347619/
Sheahan D, Bell R, Mellanby RJ, et al. Acute phase protein concentrations in dogs with nasal disease. Vet. Rec. 2010;167(23):895-899. Available from: https://pubmed.ncbi.nlm.nih.gov/21262672/
Caspi D, Snel FW, Batt RM, et al. C-reactive protein in dogs. Am. J. Vet. Res. 1987;48(6):919-921.
Holm JL, Rozanski EA, Freeman LM, et al. C-reactive protein concentrations in canine acute pancreatitis. J. Vet. Emerg. Crit. Care. 2004;14(3):183-186. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1534-6935.2004.04010.x
Kjelgaard-Hansen M, Jensen A, Houser GA, et al. Use of serum C-reactive protein as an early marker of inflammatory activity in canine type II immune-mediated polyarthritis: case report. Acta Vet. Scand. 2006;48(1);9. Available from: https://pubmed.ncbi.nlm.nih.gov/16987405/
Viitanen SJ, Lappalainen AK, Christensen MB, et al. The utility of acute-phase proteins in the assessment of treatment response in dogs with bacterial pneumonia. J. Vet. Intern. Med. 2017;31(1):124-133. Available from: https://pubmed.ncbi.nlm.nih.gov/28032360/
Suzuki K, Wakabayashi H, Takahashi M, et al. A possible treatment strategy and clinical factors to estimate the treatment response in Babesia gibsoni infection. J. Vet. Med. Sci. 2007;69(5):563-568. Available from: https://pubmed.ncbi.nlm.nih.gov/17551236/
Cerón JJ, Pardo-Marin L, Caldin M, et al. Use of acute phase proteins for the clinical assessment and management of canine leishmaniosis: general recommendations. BMC Vet. Res. 2018;14(1):196. Available from: https://pubmed.ncbi.nlm.nih.gov/29925385/
Caldin M, Tasca S, Carli E, et al. Serum acute phase protein concentrations in dogs with hyperadrenocorticism with and without concurrent inflammatory conditions. Vet. Clin. Pathol. 2009;38(1):63-68. Available from: https://pubmed.ncbi.nlm.nih.gov/19228354/
Cerón JJ, Pardo-Marin L, Wdowiak A, et al. Divergences between serum C-reactive protein and ferritin concentrations in canine pyometra. BMC Vet. Res. 2023;19(1):1-6. Available from: https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-023-03630-3
José Cerón
Dr. Cerón is a full professor at Murcia University Veterinary School and Diplomate of the European College of Veterinary Clinical Pathology Read more
Asta Tvarijonaviciute
Dr. Tvarijonaviciute is currently a lecturer in the Small Animal Internal Medicine Service at Murcia University Veterinary Teaching Hospital Read more
Blood sampling for assessment of liver status is an everyday occurrence in practice, but interpretation of the results can be more difficult than it first appears to be.
Feline hypercalcemia is commonly encountered in the clinic; this paper covers the diagnostic testing, clinical differentials, and management strategies for the condition.